MEDNAX (MD) Tops Q1 EPS by 9c; raises guidance

MEDNAX (NYSE: MD) reported Q1 EPS of $0.33, $0.09 better than the analyst estimate of $0.24. Revenue for the quarter came in at $458.36 million versus the consensus estimate of $451.44 million.

Updated 2025 Outlook

As a result of the strong first quarter 2025 performance, Pediatrix is raising its full year 2025 outlook for Adjusted EBITDA, as defined above, and now anticipates Adjusted EBITDA will be in a range of $220 million to $240 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Trilogy Metals closes $35.6M investment from U.S. Department of War